Loonstra, Floor C. http://orcid.org/0000-0002-1644-4410
Falize, Kim F.
de Ruiter, Lodewijk R. J.
Schoonheim, Menno M.
Strijbis, Eva M. M.
Killestein, Joep
de Vries, Helga E.
Uitdehaag, Bernard M. J.
Rijnsburger, Merel
Funding for this research was provided by:
GMSI (https://doi.org/10.13039/100009945)
VriendenLoterij
Dutch MS Research Foundation
VUmc Foundation
Mission Summit
Article History
Received: 9 October 2022
Revised: 2 December 2022
Accepted: 3 December 2022
First Online: 23 December 2022
Declarations
:
: F.C. Loonstra, L.R.J. de Ruiter, Eva M.M. Strijbis, H.E. de Vries and M. Rijnsburger report no disclosures. Menno Schoonheim serves on the editorial board of Frontiers of Neurology and has received research support, compensation for consulting services or speaker honoraria from the Dutch MS Research Foundation, ARSEP, Eurostars-EUREKA, ZonMW, ExceMed, Amsterdam Neuroscience, Atara, Biogen, Celgene/BMS, Merck, MedDay and Sanofi-Genzyme. B.M.J. Uitdehaag received consultancy fees from Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, Teva and Immunic Therapeutics. J. Killestein has speaker and consultancy relationships with and received research grants from Biogen, Genzyme, Immunic, Merck, Novartis, Roche, Sanofi and TEVA.
: All participants gave written informed consent and this study was approved by the Medical Ethical Committee of the Amsterdam UMC, location VUmc. This study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.